Effect of Daptomycin on Local Interleukin-6, Matrix Metalloproteinase-9, and Metallopeptidase Inhibitor 1 in Patients With MRSA-Infected Diabetic Foot

被引:14
作者
Ambrosch, Andreas [1 ,2 ]
Halevy, Daniel [3 ]
Fwity, Boushra [2 ]
Brin, Thomas [2 ]
Lobmann, Ralf [3 ]
机构
[1] Inst Lab Med Microbiol & Hyg, Regensburg, Germany
[2] Inst Lab Med & Microbiol, Bremerhaven, Germany
[3] Stuttgart Burgerhosp, Stuttgart, Germany
关键词
daptomycin; diabetic foot; MMP-9; TIMP-1; MRSA; RESISTANT STAPHYLOCOCCUS-AUREUS; COMPLICATED SKIN; RISK-FACTORS; VANCOMYCIN; EXPRESSION; ULCERS; TRIAL;
D O I
10.1177/1534734613490506
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Infection is a major cause of the diabetic foot syndrome being aggravating by the increased burden of multiresistant germs like methicillin-resistant Staphylococcus aureus (MRSA). Maximizing positive outcome for serious MRSA infections requires an aggressive treatment approach and a careful monitoring of the healing process. Therefore, we examined 8 patients with MRSA-infected diabetic foot syndrome Wagner classification grades 2 or 3 (corresponding to the Texas classification stage 2 and 3) during antibiotic treatment with daptomycin. We documented the wound size and obtained samples of wound secretion for analyses of pro-inflammatory interleukin-6 (IL-6), protease (matrix metalloproteinase-9 [MMP-9]), and antiprotease activity (metallopeptidase inhibitor 1 [TIMP-1]). During the course of anti-MRSA therapy, a decrease in the concentration of local IL-6 within the first 3 days followed by a drop of MMP-9 and an increase of TIMP-1 was observed. Finally, a reduction of wound size could be documented. The present data show that efficient antimicrobial treatment with daptomycin leads to a number of beneficial processes at the molecular level of wound healing in MRSA-infected diabetic foot ulcers.
引用
收藏
页码:100 / 105
页数:6
相关论文
共 29 条
[1]   Interleukin-6 concentrations in wound fluids rather than serological markers are useful in assessing bacterial triggers of ulcer inflammation [J].
Ambrosch, Andreas ;
Lobmann, Ralf ;
Pott, Andreas ;
Preissler, Jurgen .
INTERNATIONAL WOUND JOURNAL, 2008, 5 (01) :99-106
[2]   The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].
Arbeit, RD ;
Maki, D ;
Tally, FP ;
Campanaro, E ;
Eisenstein, BI .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681
[3]   Gelatinase concentration in tears of corneal-grafted patients [J].
Barro, CD ;
Romanet, JP ;
Fdili, A ;
Guillot, M ;
Morel, F .
CURRENT EYE RESEARCH, 1998, 17 (02) :174-182
[4]   Wound healing and its impairment in the diabetic foot [J].
Falanga, V .
LANCET, 2005, 366 (9498) :1736-1743
[5]   In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants [J].
Fluit, AC ;
Schmitz, FJ ;
Verhoef, J ;
Milatovic, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :1007-1011
[6]   Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin [J].
French, G. L. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (06) :1107-1117
[7]  
German Diabetes Association, OFF STAND WOUND INF
[8]   Comparison of microbiological results of needle puncture vs. superficial swab in infected diabetic foot ulcer with osteomyelitis [J].
Kessler, L ;
Piemont, Y ;
Ortega, F ;
Lesens, O ;
Boeri, C ;
Averous, C ;
Meyer, R ;
Hansmann, Y ;
Christmann, D ;
Gaudias, J ;
Pinget, M .
DIABETIC MEDICINE, 2006, 23 (01) :99-102
[9]  
Lavery L A, 1996, J Foot Ankle Surg, V35, P528
[10]   Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost [J].
Lipsky, B. A. ;
Tabak, Y. P. ;
Johannes, R. S. ;
Vo, L. ;
Hyde, L. ;
Weigelt, J. A. .
DIABETOLOGIA, 2010, 53 (05) :914-923